BlackRock’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-13,004
| Closed | -$112K | – | 5376 |
|
|
2024
Q1 | $112K | Sell |
13,004
-59
| -0.5% | -$282 | ﹤0.01% | 4701 |
|
|
2023
Q4 | $45.7K | Sell |
13,063
-328
| -2% | -$1.15K | ﹤0.01% | 4981 |
|
|
2023
Q3 | $47.7K | Buy |
13,391
+5
| +0% | +$27 | ﹤0.01% | 5014 |
|
|
2023
Q2 | $77.9K | Sell |
13,386
-1,905
| -12% | -$34.8K | ﹤0.01% | 4990 |
|
|
2023
Q1 | $578K | Sell |
15,291
-107
| -0.7% | -$3.51K | ﹤0.01% | 4497 |
|
|
2022
Q4 | $459K | Buy |
15,398
+194
| +1% | +$5.87K | ﹤0.01% | 4628 |
|
|
2022
Q3 | $507K | Sell |
15,204
-67
| -0.4% | -$2.56K | ﹤0.01% | 4726 |
|
|
2022
Q2 | $611K | Buy |
15,271
+290
| +2% | +$11.2K | ﹤0.01% | 4707 |
|
|
2022
Q1 | $788K | Sell |
14,981
-93
| -0.6% | -$4.68K | ﹤0.01% | 4745 |
|
|
2021
Q4 | $835K | Buy |
15,074
+110
| +0.7% | +$7.02K | ﹤0.01% | 4727 |
|
|
2021
Q3 | $1.16M | Buy |
14,964
+253
| +2% | +$21.4K | ﹤0.01% | 4514 |
|
|
2021
Q2 | $1.91M | Sell |
14,711
-1,588
| -10% | -$220K | ﹤0.01% | 4289 |
|
|
2021
Q1 | $2.68M | Hold |
16,299
| – | – | ﹤0.01% | 4192 |
|
|
2020
Q4 | $3.81M | Buy |
16,299
+16,021
| +5,763% | +$2.23M | ﹤0.01% | 3808 |
|
|
2020
Q3 | $28K | Hold |
278
| – | – | ﹤0.01% | 4675 |
|
|
2020
Q2 | $11K | Hold |
278
| – | – | ﹤0.01% | 4777 |
|
|
2020
Q1 | $9K | Hold |
278
| – | – | ﹤0.01% | 4723 |
|
|
2019
Q4 | $13K | Buy |
278
+1
| +0.4% | +$66 | ﹤0.01% | 4716 |
|
|
2019
Q3 | $25K | Buy |
277
+2
| +0.7% | +$205 | ﹤0.01% | 4620 |
|
|
2019
Q2 | $38K | Sell |
275
-234
| -46% | -$37K | ﹤0.01% | 4611 |
|
|
2019
Q1 | $140K | Sell |
509
-14
| -3% | -$3.03K | ﹤0.01% | 4318 |
|
|
2018
Q4 | $66K | Sell |
523
-2
| -0.4% | -$543 | ﹤0.01% | 4431 |
|
|
2018
Q3 | $215K | Buy |
525
+11
| +2% | +$5.09K | ﹤0.01% | 4304 |
|
|
2018
Q2 | $277K | Buy |
514
+107
| +26% | +$56.9K | ﹤0.01% | 4243 |
|
|
2018
Q1 | $187K | Sell |
407
-9
| -2% | -$4.91K | ﹤0.01% | 4224 |
|
|
2017
Q4 | $278K | Buy |
416
+7
| +2% | +$4.23K | ﹤0.01% | 4149 |
|
|
2017
Q3 | $257K | Buy |
409
+200
| +96% | +$104K | ﹤0.01% | 4178 |
|
|
2017
Q2 | $101K | Sell |
209
-1
| -0.5% | -$610 | ﹤0.01% | 4397 |
|
|
2017
Q1 | $158K | Buy |
+210
| New | +$188K | ﹤0.01% | 4262 |
|
Other funds holding TCON
BlackRock's TCON Position: Q2 2024 in Review
BlackRock sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 13,004 shares — an estimated $112K sold.
BlackRock first reported a position in TCON in Q1 2017 and held it in 29 quarters. The position peaked at $3.81M in Q4 2020. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.
- BlackRock reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- BlackRock sold 13,004 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $112K.
- BlackRock first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2017 and held it in 29 quarters.
- BlackRock's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $3.81M in Q4 2020.
- 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on BlackRock's 13F filing for Q2 2024, filed 13 Aug 2024.